GKSL Acquires 51% Stake in Patel Pharmacy & Patel Multispeciality Hospital for ₹12.5 Crore
Gujarat Kidney And Superspeciality Limited acquired 51% stakes in Patel Pharmacy for ₹3.70 crore and Patel Multispeciality Hospital and ICU for ₹8.80 crore. The total investment amounts to ₹12.50 crore. Both acquisitions are expected to strengthen GKSL's presence and diversify its business portfolio in the healthcare sector.
The acquisitions are significant in size relative to the company's likely scale, indicating a medium impact on its operations and market position.
The company is making strategic acquisitions to expand its business, which is generally viewed positively.
Gujarat Kidney And Superspeciality Limited (GKSL) announced today, February 5, 2026, that its Board of Directors has approved two significant acquisitions aimed at strengthening its presence in the healthcare sector and diversifying its business portfolio.
The company will acquire a 51% stake in Patel Pharmacy, a partnership firm, through an investment of ₹3,69,75,000 (Three crore Sixty Nine lacs Seventy five thousand only). Patel Pharmacy, established in August 2015, operates in the medical and pharmacy service provider industry. Its turnover for the financial year 2024-25 was ₹2,57,22,391.64.
In addition, GKSL will acquire a 51% stake in Patel Multispeciality Hospital and ICU, another partnership firm, by investing ₹8,79,75,000 (Eight crore Seventy Nine lacs Seventy five thousand only). This entity, also established in August 2015, is a medical and healthcare service provider with a turnover of ₹6,46,55,549.27 for FY 2024-25. The acquisition is expected to be completed within approximately two months.
Both acquisitions are considered cash considerations and are not related party transactions. The board meeting commenced at 3:30 p.m. and concluded at 4:30 p.m. on February 5, 2026.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.